Lck [p Tyr394] Antibody (755103)

HAF018). A specific band was detected for Phospho-Lck (Y394) at approximately 56 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." > HAF018). A specific band was detected for Phospho-Lck (Y394) at approximately 56 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." title="Western blot shows lysates of Jurkat human acute T cell leukemia cell line and Ramos human Burkitt's lymphoma cell line untreated (-) or treated (+) with 1 mM Pervanadate (PV) for 5 minutes. PVDF membrane was probed with 0.1 µg/mL of Mouse Anti-Human Phospho-Lck (Y394) Monoclonal Antibody (Catalog # MAB7500) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for Phospho-Lck (Y394) at approximately 56 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." />

Western blot shows lysates of Jurkat human acute T cell leukemia cell line and Ramos human Burkitt's lymphoma cell line untreated (-) or treated (+) with 1 mM Pervanadate (PV) for 5 minutes. PVDF membrane was probed with 0.1 µg/mL of Mouse Anti-Human Phospho-Lck (Y394) Monoclonal Antibody (Catalog # MAB7500) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # <a class=

NL007) and counterstained with DAPI (blue). Specific staining was localized to cell surfaces and cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells." > NL007) and counterstained with DAPI (blue). Specific staining was localized to cell surfaces and cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells." title="Lck phosphorylated at Y394 was detected in immersion fixed Jurkat human acute T cell leukemia cells treated with (upper panel) or without (lower panel) Pervanadate using Mouse Anti-Human Phospho-Lck (Y394) Monoclonal Antibody (Catalog # MAB7500) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cell surfaces and cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells." />

Lck phosphorylated at Y394 was detected in immersion fixed Jurkat human acute T cell leukemia cells treated with (upper panel) or without (lower panel) Pervanadate using Mouse Anti-Human Phospho-Lck (Y394) Monoclonal Antibody (Catalog # MAB7500) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # <a class=

• Reactivity: Hu
• Applications: WB, ICC/IF
• Clone: 755103
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

Lck [p Tyr394] Antibody (755103) Summary

• Immunogen: Phosphopeptide containing the human Lck Y394 site
  Accession # P06239
• Modification: p Tyr394
• Specificity: Detects human Lck when phosphorylated at Y394. Due to high sequence homology, this antibody may cross-react with phosphorylated members of the Src family.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: LCK
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry 8-25 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Sterile PBS to a final concentration of 0.5 mg/mL.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Lck [p Tyr394] Antibody (755103)

• EC 2.7.10
• EC 2.7.10.2
• Hck-3
• Lck
• Lcktkr
• Leukocyte C-terminal Src kinase
• LSK
• LSTRA
• Lymphocyte cell-specific protein-tyrosine kinase
• lymphocyte-specific protein tyrosine kinase
• p56(LSTRA) protein-tyrosine kinase
• p56lck
• p56-LCK
• pp58lck
• Protein YT16
• Proto-oncogene Lck
• proto-oncogene tyrosine-protein kinase LCK
• T cell-specific protein-tyrosine kinase
• T-lymphocyte specific protein tyrosine kinase p56lck
• tyrosine-protein kinase Lck
• YT16

Background

Lck (p56lck) is a 56 kDa cytosolic phosphoprotein within the Src family of non-receptor tyrosine kinases. The 509 amino acid (aa) human Lck contains an SH3 domain (aa 61-121), an SH2 domain (aa 127-224) and a protein kinase domain (aa 251-259). A short (363 aa) isoform contains alternate sequence starting at aa 348, while a 539 aa isoform contains inserted sequence after aa 321. Lck interacts with T cell CD4 and CD8 molecules and plays a pivotal role in regulating T cell activation. It can be overexpressed in cancers and functions as an oncogene. Y394 is the major site for autophosphorylation that enhances kinase activity, while Y505 is the major phosphorylation site for negative regulation.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Lck Antibody (MAB7500)(13)

Publications using MAB7500

• Rainwater, RR;Azevedo-Pouly, AC;Waldrip, ZJ;Hicks, BH;Callais, NA;Koss, B;Storey, AJ;Burdine, L;Burdine, MS; DNA-PKcs controls the cytotoxic T cell response to cancer and transplant allograft through regulating LAT-dependent signaling Cell reports 2026-01-06 [PMID: 41505255] (Western Blot, Immunocytochemistry, Human, Mouse, Transgenic Mouse)
• Zevolini, F;Onnis, A;Khazen, R;Müller, S;Marotta, G;Valitutti, S;Finetti, F;Baldari, CT; Polo-like kinase 1 regulates immune synapse assembly and cytotoxic T cell function by driving microtubule dynamics Journal of cell science 2023-12-12 [PMID: 38084966] (ICC, Western Blot, Human)
• Ye, Y;Morita, S;Chang, JJ;Buckley, PM;Wilhelm, KB;DiMaio, D;Groves, JT;Barrera, FN; Allosteric inhibition of the T cell receptor by a designed membrane ligand eLife 2023-10-05 [PMID: 37796108] (Western Blot, Human)
• Dey, G;Bharti, R;Braley, C;Alluri, R;Esakov, E;Crean-Tate, K;McCrae, K;Joehlin-Price, A;Rose, PG;Lathia, J;Gong, Z;Reizes, O; LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer Journal of ovarian research 2023-06-27 [PMID: 37370140] (Western Blot, Human)
• Caner Saygin, Giorgia Giordano, Kathryn Shimamoto, Bart Eisfelder, Anika Thomas-Toth, Girish Venkataraman et al. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia Clinical Cancer Research 8/15/2023 [PMID: 37363966]
• Caner Saygin, Giorgia Giordano, Kathryn Shimamoto, Bart Eisfelder, Anika Thomas-Toth, Girish Venkataraman et al. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia Clinical Cancer Research 2023-08-15 [PMID: 37363966] (Western Blot, Human)
• W Colon-Mora, A Baer, G Lamture, JT Stapleton, JW Fischer, N Bhattarai A short hepatitis C virus NS5A peptide expression by AAV vector modulates human T cell activation and reduces vector immunogenicity Gene Therapy, 2021-11-11;0(0):. 2021-11-11 [PMID: 34759330] (Western Blot, Human)
• KK Crean-Tate, C Braley, G Dey, E Esakov, C Saygin, A Trestan, DJ Silver, SM Turaga, EV Connor, R DeBernardo, CM Michener, PG Rose, J Lathia, O Reizes Pretreatment with LCK inhibitors chemosensitizes cisplatin-resistant endometrioid ovarian tumors Journal of ovarian research, 2021-04-22;14(1):55. 2021-04-22 [PMID: 33888137] (Western Blot, Human)
• JVS Ormonde, Z Li, C Stegen, J Madrenas TAOK3 Regulates Canonical TCR Signaling by Preventing Early SHP-1-Mediated Inactivation of LCK J. Immunol., 2018-10-29;0(0):. 2018-10-29 [PMID: 30373850] (Western Blot, Human)
• A Baer, W Colon-Mora, N Bhattarai Characterization of the effects of immunomodulatory drug fingolimod (FTY720) on human T cell receptor signaling pathways Sci Rep, 2018-07-19;8(1):10910. 2018-07-19 [PMID: 30026610] (Western Blot, Human)
• J Borlido, S Sakuma, M Raices, F Carrette, R Tinoco, LM Bradley, MA D'Angelo Nuclear pore complex-mediated modulation of TCR signaling is required for na�ve CD4+ T cell homeostasis Nat. Immunol., 2018-05-07;0(0):. 2018-05-07 [PMID: 29736031] (Western Blot, Mouse)
• N Bhattarai, JH McLinden, J Xiang, MM Mathahs, WN Schmidt, TM Kaufman, JT Stapleton Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo PLoS Pathog, 2017-02-24;13(2):e1006232. 2017-02-24 [PMID: 28235043] (Western Blot, Human)
• Clayton K, Haaland M, Douglas-Vail M, Mujib S, Chew G, Ndhlovu L, Ostrowski M T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases. J Immunol, 2013-12-13;192(2):782-91. 2013-12-13 [PMID: 24337741] (ICC, Human)

Bioinformatics

• Gene Symbol: LCK
• Uniprot:
  • P06239()